Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 6, 2005, Pages 736-745

  Flynn, J Norman ^a,b   Pistello, Mauro ^a   Isola, Patrizia ^a   Zaccaro, Lucia ^a   Del Santo, Barbara ^a   Ricci, Enrica ^a   Matteucci, Donatella ^a   Bendinelli, Mauro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 2; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS RNA;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CAT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; FIBROBLAST; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOID CELL; MODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; CAT DISEASES; CATS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, VIRAL; FEMALE; FIBROBLASTS; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; IMMUNODEFICIENCY VIRUS, FELINE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LENTIVIRUS INFECTIONS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 23844504937     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.6.736-745.2005     Document Type: Article

References (44)

1. Beatty, J. A., B. J. Willett, E. A. Gault, and O. Jarrett. 1996. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J. Virol. 70:6199-6206.
2. Borysiewicz, L. K., S. Morris, J. D. Page, and J. G. Sissons. 1983. Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity. Eur. J. Immunol. 13:804-809.
3. Brodie, S. J., D. A. Lewinsohn, B. K. Patterson, D. Jivamapa, J. Krieger, L. Corey, P. D. Greenberg, and S. R. Riddell. 1999. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:34-41.
4. Burkhard, M. J., and G. A. Dean. 2003. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr. HIV Res. 1:15-29.
5. Daenke, S., A. G. Kermode, S. E. Hall, G. Taylor, J. Weber, S. Nightingale, and C. R. Bangham. 1996. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 217:139-146.
6. Dean, G. A., A. LaVoy, and M. J. Burkhard. 2004. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT. Vet. Immunol. Immunopathol. 100:49-59.
7. Dittmer, U., B. Race, and K. J. Hasenkrug. 1999. Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus. J. Virol. 73:8435-8440.
8. Dittmer, U., B. Race, K. E. Peterson, I. M. Stromnes, R. J. Messer, and K. J. Hasenkrug. 2002. Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J. Virol. 76:450-454.
9. + T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76:2298-2305.
10. Elder, J. H., G. A. Dean, E. A. Hoover, J. A. Hoxie, M. H. Malim, L. Mathes, J. C. Neil, T. W. North, E. Sparger, M. B. Tompkins, W. A. Tompkins, J. Yamamoto, N. Yuhki, N. C. Pedersen, and R. H. Miller. 1998. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 14:797-801.
11. Evans, D. T., D. H. O'Connor, P. Jing, J. L. Dzuris, J. Sidney, J. da Silva, T. M. Allen, H. Horton, J. E. Venham, R. A. Rudersdorf, T. Vogel, C. D. Pauza, R. E. Bontrop, R. DeMars, A. Sette, A. L. Hughes, and D. I. Watkins. 1999. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5:1270-1276.
12. Flynn, J. N., J. A. Beatty, C. A. Cannon, E. B. Stephens, M. J. Hosie, J. C. Neil, and O. Jarrett. 1995. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res. Hum. Retrovir. 11:1107-1113.
13. Flynn, J. N., C. A. Cannon, J. A. Beatty, M. Mackett, M. A. Rigby, J. C. Neil, and C. Jarrett. 1994. Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J. Virol. 68:5835-5844.
14. Flynn, J. N., S. Dunham, A. Mueller, C. Cannon, and O. Jarrett. 2002. Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Vet. Immunol. Immunopathol. 85:159-170.
15. Flynn, J. N., P. Keating, M. J. Hosie, M. Mackett, E. B. Stephens, J. A. Beatty, J. C. Neil, and O. Jarrett. 1996. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J. Immunol. 157:3658-3665.
16. Gottschalk, S., O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney. 2003. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101:1905-1912.
17. Graham, E. M., O. Jarrett, and J. N. Flynn. 2003. Development of antibodies to feline IFN-gamma as tools to elucidate the cellular immune responses to FeLV. J. Immunol. Methods 279:69-78.
18. Hislop, A. D., M. F. Good, L. Mateo, J. Gardner, M. H. Gatei, R. C. Daniel, B. V. Meyers, M. F. Lavin, and A. Suhrbier. 1998. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nat. Med. 4:1193-1196.
19. Hosie, M. J., T. Dunsford, D. Klein, B. J. Willett, C. Cannon, R. Osborne, J. Macdonald, N. Spibey, N. Mackay, O. Jarrett, and J. C. Neil. 2000. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J. Virol. 74:9403-9411.
20. Hosie, M. J., and J. N. Flynn. 1996. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J. Virol. 70:7561-7568.
21. Hosie, M. J., R. Osborne, J. K. Yamamoto, J. C. Neil, and O. Jarrett. 1995. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J. Virol. 69:1253-1255.
22. Kalams, S. A. 2003. Cellular immunity for prevention and clearance of HIV infection. Curr. Mol. Med. 3:195-208.
23. Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, C. Carter, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330-336.
24. Letvin, N. L., and B. D. Walker. 2003. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat. Med. 9:861-866.
25. + T cells: correlation with viral load. J. Virol. 78:3233-3243.
26. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17.
27. Moss, D. J., A. B. Rickinson, and J. H. Pope. 1978. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int. J. Cancer 22:662-668.
28. Nickle, D. C., D. Shriner, J. E. Mittler, L. M. Frenkel, and J. I. Mullins. 2003. Importance and detection of virus reservoirs and compartments of HIV infection. Curr. Opin. Microbiol. 6:410-416.
29. Novitsky, V., H. Cao, N. Rybak, P. Gilbert, M. F. McLane, S. Gaolekwe, T. Peter, I. Thior, T. Ndung'u, R. Marlink, T. H. Lee, and M. Essex. 2002. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 76:10155-10168.
30. Peggs, K. S., and S. Mackinnon. 2002. Clinical trials with CMV-specific T cells. Cytotherapy 4:21-28.
31. Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, C. R. Rizza, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition. Nature 354:453-459.
32. Pistello, M., M. Moscardini, P. Mazzetti, F. Bonci, L. Zaccaro, P. Isola, G. Freer, S. Specter, D. Matteucci, and M. Bendinelli. 2002. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 298:84-95.
33. Regoes, R. R., R. Antia, D. A. Garber, G. Silvestri, M. B. Feinberg, and S. I. Staprans. 2004. Roles of target cells and virus-specific cellular immunity in primary simian immunodeficiency virus infection. J. Virol. 78:4866-4875.
34. Saksena, N. K., and S. J. Potter. 2003. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. 5:3-18.
35. Sarzotti, M., D. S. Robbins, and P. M. Hoffman. 1996. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271:1726-1728.
36. Stephens, E. B., E. J. Butfiloski, and E. Monck. 1992. Analysis of the amino terminal presequence of the feline immunodeficiency virus glycoprotein: effect of deletions on the intracellular transport of gp95. Virology 190:569-578.
37. Sun, Q., R. Burton, V. Reddy, and K. G. Lucas. 2002. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br. J. Haematol. 118:799-808.
38. Suni, M. A., H. S. Dunn, P. L. Orr, R. de Laat, E. Sinclair, S. A. Ghanekar, B. M. Bredt, J. F. Dunne, V. C. Maino, and H. T. Maecker. 2003. Performance of plate-based cytokine flow cytometry with automated data analysis. BMC Immunol. 4:9.
39. Tanaka, Y., S. F. Dowdy, D. C. Linehan, T. J. Eberlein, and P. S. Goedegebuure. 2003. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J. Immunol. 170:1291-1298.
40. Uhl, E. W., T. G. Heaton-Jones, R. Pu, and J. K. Yamamoto. 2002. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet. Immunol. Immunopathol. 90:113-132.
41. van Rhee, F., and J. Barrett. 2002. Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation. Cytotherapy 4:3-10.
42. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
43. Wilson, J. D., G. S. Ogg, R. L. Allen, C. Davis, S. Shaunak, J. Downie, W. Dyer, C. Workman, S. Sullivan, A. J. McMichael, and S. L. Rowland-Jones. 2000. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14:225-233.
44. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:3120-3128.